Research programme: aptamer therapeutics - RibomicAlternative Names: RBM002; RBM003
Latest Information Update: 21 Jul 2016
At a glance
- Originator Ribomic
- Class Peptide aptamers
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis; Haematological disorders
Most Recent Events
- 21 Jul 2016 Preclinical trials in Haematological disorders in Japan (unspecified route)
- 21 Jul 2016 Preclinical trials in Fibrosis in Japan (unspecified route)